Status: Recruiting
Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
Prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate safety and efficacy of candesartan in the prevention of the development of Dilated Cardiomyopathy (DCM) in genetic carriers of a DCM-causing variant without disease expression (asymptomatic)
Participants needed: 320
Trial details
Phase: Phase 3Age: 18-64Biological sex: AllType: InterventionalSponsor: Cristina Avendaño SoláUpdated: Nov 7, 2024Locations: 1
Eligibility criteria
Age: 18-64 (both included), both sexes [+4]
Hypotension (systolic arterial pressure <100 mmHg (measured following a standard... [+17]